Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,097 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Repeat Testing Clear all
Recruiting Not applicable Interventional

ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx

NCT06915038
View directory record Official record
Conditions
Squamous Cell Carcinoma of Oropharynx, HPV Positive Cancer, Throat Cancer, Tonsil Cancer
Interventions
NavDx, Adjuvant Radiation 30 Gray, Adjuvant Radiation 40 Gray
Diagnostic Test · Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Suspended Phase 1 Interventional

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

NCT06888323
View directory record Official record
Conditions
Refractory Myelodysplastic Syndrome
Interventions
Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab, Computed Tomography, Single Photon Emission Computed Tomography
Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers

NCT00527150
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline Tartrate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 28, 2026, 3:05 PM EDT
Completed Not applicable Interventional

Diabetes-Depression Care-management Adoption Trial

NCT01781013
View directory record Official record
Conditions
Depression, Diabetes Mellitus
Interventions
Technology-supported care
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
El Monte, California • Lancaster, California • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 28, 2026, 3:05 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

NCT06931340
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Androgen Therapy, Apalutamide, Docetaxel, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, PSMA PET Scan, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
213
States / cities
Tucson, Arizona • Dublin, California • Fremont, California + 172 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Novel Repetitive Synchronized Associative Stimulation Neuromodulation Approach for Spinal Cord Injury Patients

NCT06494059
View directory record Official record
Conditions
SCI - Spinal Cord Injury
Interventions
Intermittent theta burst stimulation (iTBS), Functional electrical stimulation (FES), Transcutaneous spinal cord stimulation (TSCS), Sham Intermittent theta burst stimulation (iTBS)
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Active, not recruiting Phase 1 Interventional

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

NCT01479842
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride, pharmacogenomic studies, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Kami Maddocks, MD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

NCT06723756
View directory record Official record
Conditions
Healthy Participants
Interventions
Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 28, 2026, 3:05 PM EDT
Recruiting Not applicable Interventional

Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients

NCT07455760
View directory record Official record
Conditions
Parkinson's Disease (PD), Essential Tremor
Interventions
Phoneme sequence learning, Cessation and re-enabling of stimulation of the STN, Cessation and re-enabling of stimulation of the VIM thalamic nucleus, Multisyllabic sequence learning
Behavioral · Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Results available

Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)

NCT05776862
View directory record Official record
Conditions
Spinal Cord Injuries, Tetraplegia, Paraplegia, Muscle Loss, Atrophy, Muscular, Insulin Resistance
Interventions
Ursolic Acid, Strength Training
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 28, 2026, 3:05 PM EDT
Recruiting Not applicable Interventional

Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing

NCT06896903
View directory record Official record
Conditions
ANOCA - Angina With Non-obstructive Coronary Arteries, INOCA (Ischemia With Non Obstructive Coronary Artery Disease)
Interventions
Coronary reactivity testing with and without nitrates
Diagnostic Test
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Active, not recruiting Not applicable Interventional

An Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App

NCT06098482
View directory record Official record
Conditions
Hearing Loss
Interventions
Mobile Research App (MRA), SOC/validated delivery of the speech perception test material
Device · Other
Lead sponsor
Cochlear
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
390
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 290 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin and Affect Processing in Posttraumatic Stress Disorder

NCT02546570
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 28, 2026, 3:05 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

NCT02997228
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
445
States / cities
Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Completed Not applicable Interventional Results available

Intent Recognition for Prosthesis Control

NCT05537792
View directory record Official record
Conditions
Amputation
Interventions
Robotic Knee/Ankle Prosthesis
Device
Lead sponsor
Georgia Institute of Technology
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 28, 2026, 3:05 PM EDT
Completed Phase 2 Interventional

Testing the Effects of Methylphenidate on Multiple Sclerosis

NCT02286557
View directory record Official record
Conditions
Fatigue in Multiple Sclerosis
Interventions
Methelphenidate, Placebo
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 28, 2026, 3:05 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307
View directory record Official record
Conditions
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Encinitas, California • Irvine, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants

NCT01809431
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 28, 2026, 3:05 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow

NCT01085981
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%, Topical study cream, GRAS cream
Drug
Lead sponsor
East Suburban Ob Gyn
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 28, 2026, 3:05 PM EDT
Completed No phase listed Observational

Cf-DNA Assay During Treatment of Acute Rejection

NCT04019353
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection, Kidney Transplant; Complications, Kidney Transplant Rejection, Transplant; Complication, Rejection, Transplant Dysfunction
Interventions
cf-DNA Collection
Genetic
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 28, 2026, 3:05 PM EDT
Enrolling by invitation Not applicable Interventional

Hippocampal Network Function in Epilepsy

NCT06521437
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
TMS targeting the hippocampus indirectly via its network
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 28, 2026, 3:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise-induced Hypoalgesia and Proprioceptive Changes, Comparing Isometric to Isotonic Neck Exercises

NCT06465394
View directory record Official record
Conditions
Exercise
Interventions
Exercise
Procedure
Lead sponsor
University of South Dakota
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Vermillion, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 28, 2026, 3:05 PM EDT
Recruiting Phase 2 Interventional

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

NCT07226544
View directory record Official record
Conditions
Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ivonescimab, Nephrectomy, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 3:05 PM EDT